Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06994949 · ClinicalTrials.gov registry record · Phase 1
Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus
A Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH), sponsored by Eva Sevick.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06994949 is a Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH) that is actively recruiting participants, run by Eva Sevick. The registered enrollment target is 20 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06994949, a Phase 1 study of Post-hemorrhagic Hydrocephalus (PHH), is actively recruiting participants, sponsored by Eva Sevick.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to evaluate the safety and efficacy of ventricular microdosing of indocyanine green (ICG) in order to assess cerebrospinal fluid (CSF) ventricular dynamics and extracranial CSF outflow using fluorescent Cap-based Transcranial Optical Tomography (fCTOT) and Near-InfraRed Fluorescent (NIRF) imaging and to evaluate inflammation markers of the CSF and to correlate with CSF ventricular dynamics, extracranial outflow into the lymphatics, ventriculomegaly, and patient's clinical outcome in order to understand how inflammation may impact that status of extracranial outflow.
Conditions Studied
Interventions
- DRUG ICG
- DEVICE fCTOT cap
- DEVICE NIRF planar imaging
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-01-14 |
| Est. Completion | 2029-01-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06994949
The ClinicalTrials.gov registry entry for NCT06994949 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eva Sevick, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Post-hemorrhagic Hydrocephalus (PHH) appearing as the primary indexed condition, and to 3 interventions - of which ICG is the first listed.
NCT06994949 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT06994949 about?
NCT06994949 is a clinical study titled "Assessing CSF Flow Dynamics in Pediatric Hemorrhagic Hydrocephalus". The purpose of this study is to evaluate the safety and efficacy of ventricular microdosing of indocyanine green (ICG) in order to assess cerebrospinal fluid (CSF) ventricular dynamics and extracranial CSF outflow using fluorescent Cap-based Transcranial Optical Tomography (fCTOT) and Near-InfraRed ...
What is the current status of trial NCT06994949?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2025-01-14. Estimated completion is 2029-01-03.
What conditions does trial NCT06994949 study?
This clinical trial studies the following conditions: Post-hemorrhagic Hydrocephalus (PHH).
What interventions are being tested in trial NCT06994949?
The interventions under investigation include: ICG (DRUG), fCTOT cap (DEVICE), NIRF planar imaging (DEVICE).
Who is sponsoring clinical trial NCT06994949?
This trial is sponsored by Eva Sevick, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06994949 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.